Hematopoiesis News Volume 1.43 | Nov 9 2010

    0
    32

    Hematopoiesis News 1.43, November 9, 2010.  
    In this issue: Science News  |  Current Publications  |  Industry News  |  Policy News  |  EventsSubscribe  |  Unsubscribe

    TOP STORY

    McMaster Scientists Turn Skin into Blood  ShareThis
    In an important breakthrough, scientists have discovered how to make human blood from adult human skin. [Press release from McMaster University discussing online prepublication in Nature]

    ON106-MethoCultWallchart-645x110


    SPECIAL FEATURE

    Launching ISCT’s Inaugural Commercial Development Focus Group on Peripheral Vascular Disease
    Read more on how ISCT is pursuing a greater strategic alignment with its industry members in the free ISCT Industry White Paper [International Society for Cellular Therapy]

    Interested in recruiting talented individuals? Post your career opportunities in Hematopoiesis News at no cost. Contact us at info@connexoncreative.com

    Follow us on Twitter! @Hema_News



    SCIENCE NEWS

    New Lymphoma Therapy May Be More Effective With Fewer Side Effects
    Researchers have found a combination therapy that is more effective than traditional treatments and is able to kill the cancer cells without harm to surrounding tissues. [Press release from the Weill Cornell Medical College discussing online prepublication in the Journal of Clinical Investigation]

    Mayo Clinic Finds Insufficient Vitamin D Levels in CLL Patients Linked to Cancer Progression and Death
    Researchers at Mayo Clinic have found a significant difference in cancer progression and death in chronic lymphocytic leukemia (CLL) patients who had sufficient vitamin D levels in their blood compared to those who didn’t. [Press release from Mayo Clinic discussing online prepublication in Blood]

    MethoCult® Express: Request A Sample 
    Enumerate total hematopoietic progenitors (CFC) in cord blood units in only 7 days with MethoCult® Express
    by STEMCELL Technologies
     
     
    REQUEST A SAMPLESTEMCELL Technologies Inc
     


    CURRENT PUBLICATIONS  (Ranked by Impact Factor of the Journal)

    LABORATORY RESEARCH

    Direct Conversion of Human Fibroblasts to Multilineage Blood Progenitors
    Here, researchers demonstrate the ability to generate progenitors and mature cells of the hematopoietic fate directly from human dermal fibroblasts without establishing pluripotency. [Nature]

    Murine Erythroid Short-Term Radioprotection Requires a BMP4-Dependent, Self-Renewing Population of Stress Erythroid Progenitors
    In this study, researchers found that the bone morphogenetic protein 4-dependent (BMP4-dependent) stress erythropoiesis pathway was required and specific for erythroid short-term radioprotection following bone marrow transplantation. [J Clin Invest]

    Vitamin D Insufficiency and Prognosis in Chronic Lymphocytic Leukemia (CLL)
    Researchers evaluated the relationship of 25(OH)D serum levels with time-to-treatment and overall survival in newly diagnosed CLL patients participating in a prospective cohort study(discovery cohort) and a separate cohort of previously untreated patients participating in an observational study(confirmation cohort). [Blood]

    NK-Cell Education is Shaped by Donor HLA Genotype After Unrelated Allogeneic Hematopoietic Stem-Cell Transplantation
    The rules governing natural killer (NK)-cell-education in the allogeneic environment created by unrelated hematopoietic stem-cell transplantation are still largely elusive, especially in an unrelated donor setting. The data suggest that the NK cell’s education partner could be of hematopoietic rather than extra-hematopoietic origin. [Blood]

    Chemotherapy Resistance in Acute Lymphoblastic Leukemia Requires hERG1 Channels and Is Overcome by hERG1 Blockers
    Bone marrow mesenchymal cells can protect leukemic cells from chemotherapy, thus increasing their survival rate. Researchers studied the potential molecular mechanisms underlying this effect in acute lymphoblastic leukemia cells. [Blood]

    Regulation of Hematopoietic Cell Clusters in the Placental Niche Through SCF/Kit Signaling in Embryonic Mouse
    Hematopoietic stem cells (HSCs) emerge from and expand in the mouse placenta at mid-gestation. To determine their compartment of origin and define extrinsic signals governing their commitment to this lineage, researchers identified hematopoietic cell clusters in mouse placenta, defined as cells expressing the embryonic HSC markers CD31, CD34 and Kit, by immunohistochemistry. [Development]

    Anti-Inflammatory Cytokines Hepatocyte Growth Factor and Interleukin-11 are Over-Expressed in Polycythemia Vera and Contribute to the Growth of Clonal Erythroblasts Independently of JAK2V617F
    In the present study, researchers provide evidence that inflammation-linked cytokines are required for the growth of JAK2V617F-mutated erythroid progenitors. [Oncogene]

    A DNA-Binding Mutant of TAL1 Cooperates with LMO2 to Cause T Cell Leukemia in Mice
    The data demonstrate that the DNA-binding activity of Tal1 is not required to cooperate with Lmo2 to cause leukemia in mice and suggest that Lmo2 may cooperate with Tal1 to interfere with E47/HEB function(s). [Oncogene]

    Epigenetics: Prenatal Exposure to Genistein Leaves a Permanent Signature on the Hematopoietic Lineage
    Researchers studied hematopoiesis of mice prenatally exposed to genistein (270 mg/kg feed) compared with that of mice prenatally exposed to phytoestrogen-poor feed and observed a significant increase in granulopoiesis, erythropoiesis, and mild macrocytosis at the adult age of 12 weeks. [FASEB J]

    CLINICAL RESEARCH

    Alemtuzumab Treatment of Intermediate-1 Myelodysplasia Patients Is Associated With Sustained Improvement in Blood Counts and Cytogenetic Remissions
    Researchers conducted a nonrandomized, off-label, pilot, phase I/II study of alemtuzumab monotherapy in patients with myelodysplastic syndromes who were judged likely to respond to immunosuppressive therapy based on the following criteria: HLA-DR15-negative patients whose age plus the number of months of RBC transfusion dependence (RCTD) was less than 58; and HLA-DR15-positive patients whose age plus RCTD was less than 72. [J Clin Oncol]

    A Phase II Study of High Dose Lenalidomide as Initial Therapy for Older Patients with Acute Myeloid Leukemia (AML)
    Researchers evaluated the efficacy of lenalidomide as front-line therapy for older AML patients. [Blood]


    INDUSTRY NEWS

    Ambit Biosciences Files Registration Statement for Proposed Initial Public Offering
    Ambit Biosciences Corporation announced that it has filed a registration statement with the Securities and Exchange Commission relating to the proposed initial public offering of shares of its common stock. [Ambit Biosciences Corporation Press Release]

    Coronado Biosciences, Inc. Announces Completion of Financings, Management Changes and Development Update
    Coronado Biosciences, Inc., a privately held company engaged in innovative oncology drug development, announced completion of a series of private financings in 2010, resulting in aggregate gross proceeds to the Company of approximately $21.6 million. [PRNewswire]


    POLICY NEWS

    National Institutes of Health (United States)

    Food and Drug Administration (United States)

    Center for Biologics Evaluation and Research (United States)

    European Medicines Agency (European Union)

    Medicines and Healthcare Products Regulatory Agency (United Kingdom)

    Therapeutic Goods Administration (Australia)


    EVENTS (Listed by Date)

    22nd European Organization for Research and Treatment of Cancer (EORTC)-National Cancer Institute (NCI)-American Association for Cancer Research (AACR) Symposium: Molecular Targets and Cancer Therapeutics
    November 16-19, 2010
    Berlin, Germany

    9th Annual Gene Therapy Symposium for Heart, Lung, and Blood Diseases
    November 17-19, 2010
    Sonoma, United States

    52nd American Society of Hematology (ASH) Annual Meeting and Exposition
    December 4-7, 2010
    Orlando, United States

    5th Annual Stem Cell Meeting on the Mesa
    December 7, 2010
    La Jolla, United States

    Highlights of American Society of Hematology (ASH) Vancouver
    January 21-22, 2011
    Vancouver, Canada

    Highlights of American Society of Hematology (ASH) Washington, D.C.
    January 28-29, 2011
    Washington, D.C., United States

    Highlights of American Society of Hematology (ASH) San Francisco
    January 28-29, 2011
    San Francisco, United States

    Highlights of American Society of Hematology (ASH) New York
    February 4-5, 2011
    New York, United States

    Highlights of American Society of Hematology (ASH) San Diego
    February 4-5, 2011
    San Diego, United States

    BMT Tandem Meetings (ASBMT/CIBMTR)
    February 17-21, 2011
    Honolulu, Hawaii

    Molecular Medicine Tri-Conference: Inaugural Circulating Tumor Cells for Cancer Detection, Diagnosis, Prognosis and Treatment
    February 23-25, 2011
    San Francisco, United States

    American Association for Cancer Research (AACR) Stem Cells, Development, and Cancer
    March 3-6, 2011
    Vancouver, Canada

    Keystone Symposia: Hematopoiesis
    March 27-April 1, 2011
    Big Sky, United States

    United Kingdom National Stem Cell Network 2011 Annual Scientific Conference
    March 30-April 1, 2011
    York, United Kingdom

    American Association for Cancer Research (AACR) 102nd Annual Meeting 2011
    April 2-6, 2011
    Orlando, United States

    37th Annual Meeting of the European Group for Blood and Marrow Transplantation
    April 3-6, 2011
    Paris, France

    International Society for Stem Cell Research (ISSCR) 9th Annual Meeting
    June 15-18, 2011
    Toronto, Canada

    Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.

    JOB OPPORTUNITIES

    Lab Technologist – Human Embryonic and Induced Pluripotent Stem Cells (STEMCELL Technologies)

    Lab Technologist – Tissue Culture (STEMCELL Technologies)


    Product Manager – Pluripotent Stem Cells (STEMCELL Technologies)

    Business Manager – Centre for Blood Cell Therapies (Cell Therapies)

    Recruit Top Talent
    Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Cell Therapy News at no cost.

    Visit  here to post your career opportunities.


    Have we missed an important article or publication in Hematopoiesis News? Click here to submit!




    Comments or Suggestions? Email info@connexoncreative.com with your feedback.


    Learn more about Hematopoiesis News: Archives  |  Events  |  Subscribe  |  Contact Us